Фармакоэкономическая эффективность атипичных антипсихотиков у больных шизофренией
Abstract
Проведён сравнительный фармакоэкономический анализ применения атипичных антипсихотиков у больных шизофренией.
About the Authors
Ю. Белоусов
ГОУ ВПО «Российский национальный исследовательский медицинский университет имени Н.И. Пирогова», Москва
Russian Federation
Russian Federation
Д. Белоусов
http://www.healtheconomics.ru/
ООО "Центр фармакоэкономических исследований", г. Москва
Russian Federation
ООО "Центр фармакоэкономических исследований", г. Москва
Russian Federation
В. Омельяновский
Российский государственный медицинский университет, г. Москва
Russian Federation
Russian Federation
References
1. American Psychiatric Association. Practice guidelines for the treatment of patients with schizophrenia. Am J Psychiatry 1997 Apr; 154 Suppl. 4: 1-63.
2. Chakos M., Lieberman J., Hoffman E., Bradford D., Sheitman B. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am J Psychiatry 2001;158: 518-26.
3. Davis J.M., Chen N., Glick I.D. A metaanalysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003; 60:553-64.
4. Davis J.M., Matalon L., Watanabe M.D., et al. Depot antipsychotic drugs: place in therapy. Drugs 1994 May; 47 (5): 741-73.
5. Duncan J.C., Rogers R. Medication compliance in patients with chronic schizophrenia: implications for the community management of mentally disordered offenders. J Forensic Sci 1998 Nov; 46 (3): 1133-7.
6. Edwards N., Locklear J., Rupnow M., Diamond R., et al. Cost-effectiveness evaluation of long-acting risperidone. Poster presentation for Financing Mental and Addictive Disorders; Venice, Italy, Scuola Grande di San Giovanni Evangelista, March 18-20, 2005.
7. Edwards N., Rupnow M., Locklear J., et al. Cost-effectiveness evaluation of long-acting risperidone. [Poster] Presented at ISPOR 9th Annual International Meeting. May 2004, Washington, D.C.
8. Edwards N., Rupnow M., Pashos C., et al. Cost-effectiveness evaluation of long-acting risperidone. Pharmacoeconomics 2005: 23 (3): 299-314.
9. Ereshefsky L., Saklad S.R., Jann M.W., et al. Future of depot neuroleptic therapy: pharmacokinetic and pharmacodynamic approaches. J Clin Psychiatry 1984 May; 45 (5 Pt 2): 50-9.
10. Geddes J., Freemantle N., Harrison P., Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000;321: 1371-6.
11. Glazer W.M., Kane J.M. Depot neuroleptic therapy: an underutilized treatment option. J Clin Psychiatry 1992 Dec; 53 (12): 426-33.
12. Hogarty G.E., Anderson C.M., Reiss D.J., et al. Family psychoeducation, social skills training, and maintenance chemotherapy in the aftercare treatment of schizophrenia: II. Two-year effects of a controlled study on relapse and adjustment. Environmental-Personal Indicators in the Course of Schizophrenia (EPICS) Research Group. Arch Gen Psychiatry 1991 Apr; 48 (4): 340-7.
13. Hogarty G.E., Schooler N.R., Ulrich R., et al. Fluphenazine and social therapy in the aftercare of schizophrenic patients: relapse analyses of a wo-year controlled study of fluphenazine decanoate and fluphenazine hydrochloride. Arch Gen Psychiatry 1979 Nov; 36 (12): 1283-94.
14. Johnson D.A., Pasterski G., Ludlow J.M., et al. The discontinuance of maintenance neuroleptic therapy in chronic schizophrenic patients: drug and social consequences. Acta Psychiatr Scand 1983 May; 67 (5): 339-52.
15. Kane J., Honigfeld G., Singer J., Meltzer H. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45: 789-96.
16. Kelly G.R., Scott J.E., Mamon J. Medication compliance and health education among outpatients with chronic mental disorders. Med Care 1990 Dec; 28 (12): 1181-97.
17. Kendler K.S., Gallagher T.J., Abelson J.M., et al. Lifetime prevalence, demographic risk factors, and diagnostic validity of nonaffective psychosis as assessed in a US community sample: the National Comorbidity Survey. Arch Gen Psychiatry 1996 Nov; 53 (11): 1022-31.
18. Kissling W. Compliance, quality assurance and standards for relapse prevention in schizophrenia. Acta Psychiatr Scand 1997; 89 Suppl. 382: 16-24.
19. Lehman A.F., Steinwachs D.M. Translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. Schizophr Bull 1998; 24 (1): 1-10.
20. Leucht S., Barnes T.R.E., Kissling W., Engel R.R., Correll C., Kane J.M. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry 2003; 160: 1209-22.
21. Leucht S., Pitschel-Walz G., Abraham D., Kissling W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo: a meta-analysis of randomized controlled trials. Schizophr Res 1999;35: 51-68.
22. Leucht S., Wahlbeck K., Hamann J., Kissling W. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 2003; 361: 1581-9.
23. Lieberman J.A., Stroup T.S., McEvoy J.P., Swartz M.S., Rosenheck R.A., Perkins D.O., Keefe R.S.E., Davis S.M., Davis C.E., Lebowitz B.D., Severe J., Hsiao J.K. Эффективность антипсихотических препаратов у больных хронической шизофренией. Расширенный реферат с комментариями С.Н. Мосолова//Терапия психических расстройств. №1. 2006.(http://www.psychiatry-therapy.ru/archive/n1-2006/n1-2006_160.html).
24. Miller A.L., Chiles J.A., Chiles J.K., et al. The Texas Medication Algorithm Project (TMAP) schizophrenia algorithms. J Clin Psychiatry 1999 Oct; 60 (10): 649-57.
25. Miyamoto S., Duncan G.E., Marx C.E., Lieberman J.A. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry 2005;10: 79-104.
26. Olivares J.M., Rodriguez A., Povey M., Diels J, Jacobs A on behalf of the e-STAR study group. 6-month follow-up from the electronic-Schizophrenia Adherence Treatment Registry (e-STAR) of patients in Spain who were initiated to Risperidone Long-Acting Injection (RLAI).//9th ISPOR European Congress, Copenhagen, Denmark, 28-31 October 2006. e-STAR Spain cohort, Draft 1, 09 June 06.
27. Rosenheck R., Perlick D., Bingham S., et al. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. JAMA 2003;290: 2693-702.
28. Scottish Schizophrenia Research Group. The Scottish First Episode Schizophrenia Study, II: treatment: pimozide versus flupenthixol. Br J Psychiatry 1987 Mar; 150: 334-8.
29. Tollefson G.D., Sanger T.M. Negative symptoms: a path analytic approach to a double-blind, placebo-and haloperidolcontrolled clinical trial with olanzapine. Am J Psychiatry 1997;154: 466-74.
30. Tuunainen A., Wahlbeck K., Gilbody S. Newer atypical antipsychotic medication in comparison to clozapine: a systematic review of randomized trials. Schizophr Res 2002;56: 1-10.
31. Wahlbeck K., Cheine M., Essali A., Adams C. Evidence of clozapine's effectiveness in schizophrenia: a systematic review and meta-analysis of randomized trials. Am J Psychiatry 1999;156: 990-9.
32. Weiden P.J., Dixon L., Frances A., et al. Neuroleptic noncompliance in schizophrenia. In: Tamming CA, Schulz SC, editors. Advances in neuropsychiatry and psychopharmacology: schizophrenia research. Vol. 1, New York: Raven Press, 1991: 285-96.
33. Weiden P.J., Olfson M. Cost of relapse in schizophrenia. Schizophr Bull 1995; 21 (3): 419-29.
34. http://www.medlux.ru/ от 20.01.2007 г.
35. Young J.L., Zonana H.V., Shepler L. Medication noncompliance in schizophrenia: codification and update. Bull Am Acad Psychiatry Law 1986; 14 (2): 105-22.
36. Yousef H.A. A five-year follow-up study of chronic schizophrenics and other psychotics treated in the community: depot haloperidol decanoate versus other neuroleptics. Adv Ther 1989; 67: 186-95.
37. Зозуля Т.В. Эпидемиологическое исследование психически больных пожилого и старческого возраста и вопросы организации медико-социальной помощи: Автореф. дис.... д-ра мед.наук. Москва, 1998.
38. Прейскурант на оказание медицинских услуг клиники Научного центра психического здоровья РАМН. Москва, 2006 г.
39. Прейскурант на оказании медицинских услуг больницы им. Боткина, 2006 г.
40. Рытик Э.Г. Разработка клинико-статистических групп для оценки деятельности психиатрических стационаров: Автореф. дис.... д-ра мед.наук. Москва, 1993.
41. Стандарты оказания помощи больным шизофренией. Московский НИИ психиатрии Росздрава./Под редакцией В.Н.Краснова, И.Я. Гуровича, С.Н. Мосолова, А.Б. Шмуклера. Москва, 2006 г.
42. Краснов С.Ю. Новые Санкт-Петербургские ведомости. 2004. № 4. С. 16-18.
43. Rossler W., Salize H.J., van Os J., Riecher-Rossler A. Бремя шизофрении и психотических расстройств в странах Евросоюза (расширенный реферат)//Психиатрия и фармакотерапия. 2006. Т. 11, № 2.
44. Fleishhacker W.W., Eerdeckens M., Karcher K., et al. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. J Clin Psychiatry 2003 Oct; 64 (10): 1250-7.
Review
For citations:
, , . Kachestvennaya Klinicheskaya Praktika = Good Clinical Practice. 2006;(2):60-71. (In Russ.)
Views:
2508
Email this article 